Our Pricing

Order Weight Loss Injections Through NHS Pathway

Published on: June 03, 2026

When you order weight loss injections through NHS pathway services at Cured Pharmacy, you're accessing the same clinical standards and prescription protocols used across NHS services, delivered through our UK-registered pharmacy. Our GPhC-registered team provides free online consultations with UK prescribers, ensuring every patient receives appropriate clinical assessment before dispensing MHRA-licensed weight loss treatments including Mounjaro, Wegovy, and Saxenda.

How NHS Pathway Weight Loss Injections Work

NHS pathway services follow strict NICE guidelines for prescribing weight loss medications, requiring comprehensive clinical assessment before treatment approval. At Cured Pharmacy, our UK-registered prescribers apply identical eligibility criteria used in NHS weight management programmes, evaluating your BMI, medical history, previous weight loss attempts, and contraindications [1].

The most prescribed weight loss injections through NHS pathways are GLP-1 receptor agonists — medications that mimic natural gut hormones to regulate appetite and blood sugar. Tirzepatide (Mounjaro) works as a dual GIP/GLP-1 agonist, whilst semaglutide (Wegovy) and liraglutide (Saxenda) target GLP-1 receptors alone. Clinical trials demonstrate these treatments produce significantly greater weight reduction than lifestyle modification alone when used as part of comprehensive weight management programmes [2].

Your prescription pathway begins with a three-minute online consultation where you'll answer detailed medical questions reviewed by our UK prescribers. If clinically appropriate, your prescription is issued electronically and dispensed from our Leicester-based pharmacy with discreet next-day delivery across the UK.

Eligibility Criteria for Weight Loss Injection Prescriptions

Following NICE guidance, weight loss injections are typically prescribed for adults with a BMI of 30 kg/m² or above, or 27 kg/m² with weight-related health conditions such as type 2 diabetes, hypertension, or obstructive sleep apnoea [3]. Our UK prescribers assess each patient individually, considering medical history, current medications, and treatment goals.

Certain medical conditions may affect eligibility. Patients with personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, severe gastrointestinal disease, or diabetic retinopathy require careful evaluation. Pregnancy, breastfeeding, and plans to conceive are contraindications for GLP-1 treatments. Your online consultation captures these essential details to ensure safe prescribing.

Previous weight loss attempts are documented as part of the NHS pathway approach. NICE recommends these medications as adjuncts to reduced-calorie diets and increased physical activity, not standalone solutions. Our prescribers discuss realistic expectations and the importance of sustained lifestyle modification alongside pharmacological treatment.

BMI Requirements and Medical Exceptions

Whilst standard BMI thresholds apply to most patients, certain ethnic groups face higher metabolic risks at lower BMI levels. For adults of South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean family background, treatment may be considered at BMI 27.5 kg/m² without comorbidities, or 25 kg/m² with weight-related conditions [3]. Our clinical assessment captures ethnicity data to apply appropriate thresholds during prescription review.

Mounjaro, Wegovy, and Saxenda: Clinical Efficacy Compared

Mounjaro (tirzepatide) represents the latest advancement in weight loss pharmacotherapy, demonstrating superior efficacy in head-to-head trials. The SURPASS-2 study showed tirzepatide 15mg produced average weight reduction of 12.4kg compared to 6.2kg with semaglutide 1mg over 40 weeks in patients with type 2 diabetes [4]. In obesity-specific trials (SURMOUNT-1), participants without diabetes achieved up to 22.5% body weight reduction over 72 weeks on the highest tirzepatide dose [1].

Wegovy (semaglutide 2.4mg) demonstrated robust efficacy in the STEP trial programme, with average weight loss of 14.9% over 68 weeks when combined with lifestyle intervention [2]. This represented a significant improvement over the 2.4% seen with placebo plus lifestyle changes. Approximately one-third of participants achieved 20% or greater weight reduction, meeting thresholds typically seen only with bariatric surgery.

Saxenda (liraglutide 3mg) requires daily subcutaneous injection rather than weekly administration. The SCALE trial showed average weight loss of 8% over 56 weeks, with 63.2% of participants achieving at least 5% weight reduction [5]. Whilst efficacy is lower than newer dual-agonist treatments, Saxenda remains clinically valuable for patients who prefer daily dosing or cannot tolerate higher-potency alternatives.

Choosing Between Injectable Options

Treatment selection depends on individual clinical factors, tolerability profiles, and cost considerations. Patients seeking maximum weight reduction based on current evidence may be prescribed tirzepatide subject to prescriber assessment. Those prioritising established safety data and NHS formulary alignment may prefer semaglutide. Your UK prescriber discusses these options during consultation, recommending treatment based on your medical profile rather than cost alone.

How to Order Weight Loss Injections Through Our NHS Pathway Service

Starting your prescription journey at Cured Pharmacy takes under three minutes. Click 'Start Assessment' on any weight loss injection product page to begin the online consultation. You'll answer comprehensive medical questions covering your weight history, current health conditions, medications, allergies, and treatment goals. This questionnaire follows the same clinical assessment framework used in NHS weight management services.

A UK-registered prescriber reviews your consultation within hours during working days. If your medical history indicates safe, appropriate use, your prescription is issued electronically to our Leicester pharmacy. You'll receive email confirmation with treatment instructions and expected delivery date. All pricing is displayed upfront before consultation — Mounjaro from £135.00, Wegovy from £135.00, and Saxenda from £135.00 — with no hidden fees or subscription requirements.

If the prescriber determines weight loss injections are not clinically appropriate based on your assessment, you'll receive a full refund and explanation. Alternative treatments such as Orlistat may be recommended depending on your BMI and medical profile. This clinical governance mirrors NHS prescribing standards, prioritising patient safety over commercial interests.

What to Expect During Treatment: Dosing and Side Effects

All GLP-1 weight loss injections follow gradual dose escalation protocols to minimise gastrointestinal side effects. Mounjaro starts at 2.5mg weekly for four weeks, increasing to 5mg, then potentially 7.5mg, 10mg, 12.5mg, or 15mg based on tolerability and efficacy. Wegovy begins at 0.25mg weekly, escalating monthly to a maintenance dose of 2.4mg. Saxenda starts at 0.6mg daily, increasing by 0.6mg increments to 3mg daily [1][2][5].

The most common side effects are gastrointestinal: nausea, diarrhoea, constipation, vomiting, and abdominal discomfort. These typically occur during dose escalation and diminish over weeks as your body adapts. Eating smaller meals, avoiding high-fat foods, and staying well-hydrated helps manage symptoms. Severe or persistent vomiting requires medical review, as dehydration can occur rapidly.

Rare but serious adverse effects include pancreatitis, gallbladder disease, and hypoglycaemia in patients taking concurrent diabetes medications. Warning signs of pancreatitis include severe persistent abdominal pain radiating to the back. Symptoms of gallstones include right upper abdominal pain, particularly after fatty meals. Contact your prescriber immediately if you experience these symptoms. Regular clinical review every 12 weeks ensures ongoing treatment appropriateness and monitoring for adverse effects.

Injection Technique and Storage Requirements

Weight loss injections are administered subcutaneously into the abdomen, thigh, or upper arm. Rotate injection sites weekly to prevent lipohypertrophy. Your medication arrives with detailed patient information leaflets and injection instructions. Pens should be stored in the refrigerator at 2-8°C, never frozen. Once in use, Saxenda pens may be kept at room temperature below 30°C for 30 days. Mounjaro and Wegovy pens can remain at room temperature below 30°C for 21 days after first use. Always check the patient information leaflet supplied with your specific product for authoritative storage guidance.

Cost Comparison and Transparent Pricing at Cured Pharmacy

Weight loss injection pricing varies significantly across UK pharmacies, with many services hiding costs behind mandatory consultations. At Cured Pharmacy, all prices are displayed upfront before you begin assessment. Our superintendent pharmacist Tarun Kumar (GPhC 2233073) ensures competitive pricing without compromising on clinical standards or medication authenticity.

Mounjaro treatment at Cured Pharmacy starts from £135.00 per four-week supply, representing lower than typical market rates for this newest dual-agonist therapy. Wegovy is available from £135.00, reduced from £135.00, providing significant savings on this established semaglutide treatment. Saxenda starts from £135.00 for patients preferring daily injection regimens. These prices include UK prescriber consultation, electronic prescription, and discreet delivery with no subscription lock-ins.

For patients seeking non-injectable alternatives, Orlistat capsules start from £135.00, with branded Xenical from £135.00. Orlistat works through a different mechanism — blocking dietary fat absorption — and may be appropriate for those unable to tolerate GLP-1 treatments. Your online consultation determines which treatment offers the best clinical fit for your individual circumstances.

All medications dispensed by Cured Pharmacy are genuine UK-licensed products sourced through regulated wholesalers. We never supply unlicensed imports or compounded alternatives. Your safety and treatment efficacy depend on authentic medications, which is why we maintain full traceability on every product leaving our GPhC-registered premises (9012511).

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
2. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
3. National Institute for Health and Care Excellence. (2023). Obesity: identification, assessment and management (Clinical guideline CG189). NICE. https://www.nice.org.uk/guidance/cg189 [accessed 13 August 2026]
4. Frías, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519 [accessed 13 August 2026]
5. Pi-Sunyer, X., Astrup, A., Fujioka, K., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892 [accessed 13 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Weight loss results vary between individuals and depend on adherence to treatment, dietary modification, and physical activity levels.